Trial Profile
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Acronyms HICARE-Trial
- 09 Apr 2016 Status changed from suspended to completed, as reported by European Clinical Trials Database.
- 01 Aug 2015 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
- 09 Mar 2012 Additional lead trial centre (iOMEDICO) and investigator (Jurgen Debus) identified as reported by ClinicalTrials.gov.